Positive PhIII Data For Pfizer's Xeljanz In Psoriatic Arthritis
This article was originally published in Scrip
Pfizer has reported positive top-line data from the first of three Phase III trial of Xeljanz (tofacitinib) in psoriatic arthritis. The product has been approved for rheumatoid arthritis since 2012 but sales had initially struggled to take off in a category dominated by blockbuster injectable tumor necrosis factor inhibitors.
Register for our free email digests: